STAT Plus: Pharmalittle: FDA approves another Duchenne muscular dystrophy drug; European orphan drug incentives questioned
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Category: STAT Plus
STAT Plus: ‘We’re going to keep going’: A new clinical trial for ALS gives patients hope
As a cardiologist, Dr. Marc Litt has plenty of arrows in his quiver for patients…
STAT Plus: A long-awaited report on orphan drugs in Europe suggests incentives to pharma need change
After being kept under wraps for a year, an expansive review of European regulations designed…
STAT Plus: Pharmalittle: Moderna gets $1.5 billion U.S. contract for Covid-19 vax; state out-of-pocket caps saved residents money
Hello, everyone, and how are you today? A bright shiny sun and cool breezes are…
STAT Plus: 4 questions for neurology startups as venture investors pour millions into the field
As pharmaceutical companies stepped back from developing new drugs for neurological conditions, venture capitalists took…
STAT Plus: Out-of-pocket spending on specialty drugs dropped dramatically after states capped costs
Amid efforts to blunt rising medicines costs, a new analysis finds three states succeeded in…
STAT Plus: Pharmalittle: Russia registers a Covid-19 vaccine amid skepticism; can monoclonal antibodies combat the coronavirus?
Rise and shine, everyone, another demanding day is on the way. We can tell if…
STAT Plus: With Livongo’s arsenal of health devices, Teladoc is poised to move into remote monitoring
As part of its landmark $18.5 billion deal to buy Livongo, telehealth giant Teladoc Health…
STAT Plus: AAMC, the medical school trade association, gave $500,000 to dark-money group in 2018
WASHINGTON — The dark-money group Citizens for Truth in Drug Pricing, which has run several…
STAT Plus: Seizing on India’s lax standards for Covid-19 drugs, critics push for an overhaul on transparency
As Indian regulators endorse controversial treatments for Covid-19, a group of high-profile physicians and activists…
STAT Plus: Pharmalittle: One in three Americans would refuse a Covid-19 vaccine; pharma donates big-time to Congress
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Seres announces positive late-stage results for its microbe-based drug
Four years after a devastating clinical trial failure, Seres Therapeutics seems to have found success….
STAT Plus: FDA’s reopening plan will keep biologics labs shuttered far longer than other government labs
WASHINGTON — The FDA is keeping its biologics labs shuttered far longer than other government…
STAT Plus: FDA approves first oral treatment for a rare muscle-destroying disease
The Food and Drug Administration on Friday approved the first oral therapy for spinal muscular…
STAT Plus: Hospital president wrote opinion piece critical of drug pricing efforts, but didn’t disclose role on Moderna board
Dr. Elizabeth Nabel, president of Brigham and Women’s Hospital, earlier this year criticized efforts to…
STAT Plus: Pharmalittle: Trump’s ‘Buy American’ order raises doubts; Gilead looks to boost global remdesivir output
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: AbbVie pays $24 million to settle lawsuit over using ‘nurse ambassadors’ to boost Humira sales
After two years of wrangling, AbbVie (ABBV) agreed to pay $24 million to settle a…
STAT Plus: Italy becomes first country to require pharma to disclose public funding for R&D costs
Amid growing clamor for more transparency from the pharmaceutical industry, Italy has become the first…
STAT Plus: Pressure mounts on FDA chief to stick with science for Covid-19 vaccine approvals
As pressure mounts to develop a successful Covid-19 vaccine, Food and Drug Administration Commissioner Stephen…
STAT Plus: Biogen strikes $1 billion deal with Denali to advance Parkinson’s drug based on approach that was nearly abandoned
Biogen said Thursday it will pay more than $1 billion to the biotech firm Denali…
STAT Plus: Pharmalittle: AstraZeneca strikes first Covid-19 deal with a Chinese company; vaccine trials face distrust from minority groups
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT Plus: 10 burning questions about Teladoc’s $18.5 billion deal to buy Livongo
It’s hard to recall a deal that scrambled the dynamics of the health tech industry…
STAT Plus: Pharmalittle: J&J to supply U.S. with 100 million Covid-19 vaccine doses; Feds seek $18 billion from Purdue in opioid probe
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
STAT Plus: Earnings season highlights how health tech companies fared in the first full quarter of the pandemic
It’s earnings season for health tech companies — and that’s opening a window into how…
STAT Plus: Haven was supposed to reimagine health care. An exodus of talent has gutted it
Haven, the audacious health venture founded by three of America’s most storied companies, was once…
STAT Plus: Scientists are testing pricey rare-disease drugs as Covid-19 treatments. What if one works?
Some of the existing drugs scientists are testing as Covid-19 treatments have a special status…
STAT Plus: State attorneys general urge HHS to sidestep Gilead patents to increase remdesivir access
A bipartisan group of state attorneys general is urging the federal government to sidestep the…
STAT Plus: The FDA is finalizing its long-awaited rules for CBD
A version of this story first ran in D.C. Diagnosis, STAT’s weekly newsletter about the…
STAT Plus: BARDA faces pressure to force Moderna to disclose cost details from its Covid-19 contract
Amid concerns over U.S. government Covid-19 contracts and transparency, Moderna (MRNA) has failed to comply…
STAT Plus: Pharmalittle: Regeneron Covid-19 antibody treatment works in animals; Warren asks SEC to probe Kodak trading
Top of the morning to you, and a fine one it is. Despite a looming…
STAT Plus: Prescription drugs may be more affordable than you think — unless you pay cash
Amid growing complaints that many Americans cannot afford their prescription medicines, most people in the…
STAT Plus: Gilead faces renewed pressure to pursue remdesivir-like compound to fight Covid-19
In an unusual move, a pair of academics is escalating an effort to convince Gilead…
STAT Plus: Justice Department probes Sanofi and GlaxoSmithKline over possible carcinogen in Zantac pills
The Department of Justice has started investigating whether drug makers failed to disclose information about…
STAT Plus: Pharmalittle: Lilly starts late-stage trial of Covid-19 antibody; concern grows over political intervention on Covid-19 vaccine
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Music in drug ads makes it easier for the public to tune out side effects, advocates argue
This will not be music to the ears of the pharmaceutical industry. A pair of…
STAT Plus: In a blow to Catalyst, judge recommends tossing its lawsuit against FDA
A federal court judge recommended tossing out a lawsuit filed by Catalyst Pharmaceuticals (CPRX) that…
STAT Plus: Pharmalittle: U.S. hands Glaxo and Sanofi $2.1 billion for a Covid-19 vaccine; Moderna director resigns over conflict concerns
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: CytoDyn CEO claims Covid-19 drug success while describing data suggesting study failure
CytoDyn CEO Nader Pourhassan used a conference call on Thursday evening to claim success with the…
STAT Plus: The drug industry’s new tactic in Washington: calling Trump’s bluff
WASHINGTON — The pharmaceutical industry has sparred with President Trump for four years over drug…
STAT Plus: Prominent hospital president resigns from Moderna board after conflict of interest questions raised
Dr. Elizabeth Nabel, president of Brigham and Women’s Hospital, said Thursday she was resigning from…
STAT Plus: Pharmalittle: Drug makers build Covid-19 vaccine supply chains; VCs are still spending on biotechs
Hello, everyone, and how are you today? We are doing just fine, thank you, despite…
STAT Plus: Coles-led Cerevel Therapeutics to raise $445 million to develop brain drugs with fewer side effects
Cerevel Therapeutics, a Boston neuroscience company spun out from Pfizer in 2018 and led by…
STAT Plus: Drug maker settles charges of offering ‘bogus’ research grants to boost use of its medicine
In the latest imbroglio involving drug makers and kickbacks, Pacira Biosciences (PCRX) has agreed to…
STAT Plus: Venture capitalists are still showering biotechs with cash, even as the coronavirus upends markets
Venture capitalists are still spending big on biotech companies, even four months after the coronavirus…
STAT Plus: Seeking to battle high drug prices and the opioid crisis, two states ponder banning gifts to doctors
Over the past month, lawmakers in two states have introduced bills that would ban drug…
STAT Plus: MacKenzie Scott, with a massive Amazon fortune, emerges as a public health philanthropist
You may not know the name MacKenzie Scott – the author just started going by…
.jpg)
STAT Plus: Pharmalittle: Global supply chain not ready for Covid-19 vaccines; Moderna may price its vaccine at up to $60
Good morning, everyone, and welcome to the middle of the week. You made it this…
STAT Plus: Cancer drug is the first potential therapy to emerge from 23andMe and GlaxoSmithKline collaboration
The pharmaceutical giant GlaxoSmithKline is starting human trials of the first medicine, a cancer drug,…
STAT Plus: Better than the rest or behind the competition? Moderna’s future hinges on how its Covid-19 vaccine fares
Among the pharmaceutical companies closest to developing a Covid-19 vaccine, none has more riding on…
STAT Plus: Harry Reid and Alex Trebek tried Patrick Soon-Shiong’s experimental cancer therapy. Can their results be duplicated in a clinical trial?
Former Senate Majority Leader Harry Reid’s pancreatic cancer went into remission. “Jeopardy!” host Alex Trebek,…